Third time lucky for AstraZeneca and its Lokelma hyperkalaemia treatment

The US Food and Drug Administration had twice rejected AstraZeneca’s applications for Lokelma due to issues at the manufacturing plant in Texas

Astra thinks Lokelma can be a blockbuster drug, bringing in more than US$1bn a year

AstraZeneca PLC (LON:AZN) has finally received approval from the US Food and Drug Administration for its Lokelma hyperkalaemia treatment.

The drug, formerly known as ZS-9, had been rejected two times previously by regulators, casting doubt over Astra’s US$2.7bn acquisition of ZS Pharma back in 2015, which it primarily bought to gain access to the compound.

READ: FDA deals another blow to Astra’s ZS-9 drug

“We are pleased by today's FDA approval of Lokelma as it enables us to help address a long-standing clinical need with a new medicine that offers rapid and sustained treatment for adults with hyperkalaemia,” said chief medical officer Sean Bohen.

“The consequences of hyperkalaemia can be very serious and it's reassuring for treating physicians that Lokelma has demonstrated lowering of potassium levels in patients with chronic kidney disease, heart failure, diabetes and those taking RAAS inhibitors.”

Hyperkalaemia is a condition where potassium levels in the blood are dangerously high and can threaten kidney and heart function.

Blockbuster potential

Astra reckons it can generate peak sales in excess of US$1bn a year, with some analysts claiming that the total market is worth upwards of US$6bn.

The approval is key for Astra, which is still in the process of filling the void left by declining sales of its previous blockbusters Crestor and Seroquel drugs.

News of the approval comes just a few days after the FTSE 100 drugmaker reported a sharp fall in first-quarter revenues and earnings per share.

Quick facts: AstraZeneca

Price: 7222 GBX

Market: LSE
Market Cap: £94.75 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole...

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan. The investment will help get the company’s next-generation antibiotic through phase III clinical...

5 hours, 44 minutes ago

2 min read